Skin rash treatment for people taking cancer drugs
Part of Skin clinical trials.
This study tests a new cream, ATR04-484, to see if it can help with skin rashes caused by certain cancer medications (EGFR inhibitors, KRAS inhibitors, or MEK inhibitors). If you have a moderate to severe rash on your face or other areas from these drugs, this trial may offer a new way to ease your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently taking an FDA-approved EGFR, KRAS, or MEK inhibitor for cancer or neurofibromatosis, and will keep taking it during the study.
- You have a grade 2 or 3 skin rash (moderate to severe) on your face, which may also spread to neck, chest, or back. Some patients with mild rash may be allowed.
- You have not used strong topical steroids, antibiotic creams, or antibacterial washes on your face, neck, chest, or back in the past 7 days.
- You have not taken oral antibiotics or steroids in the past 7 days.
- You do not live with someone who has a weakened immune system during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This study tests a moisturizing cream (with pre- and postbiotics and niacinamide) to see if it reduces dryness and itching in cancer patients who are on a type of targeted therapy called anti-EGFR drugs. If you have dry, itchy skin from your treatment, this cream might help soothe it.
This trial tests whether extra care to prevent skin and infusion side effects helps people with advanced lung cancer who are getting amivantamab (with lazertinib or chemotherapy). It aims to make these treatments easier to tolerate.
This trial compares two oral medications, isotretinoin and doxycycline, to treat a specific type of skin rash (acne-like) caused by cancer treatments that target the MAPK pathway. The study aims to find the best way to clear the rash and improve comfort.
Hear when a new EGFR Inhibitor-associated Rash trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.